Copyright
©The Author(s) 2020.
World J Meta-Anal. Jun 28, 2020; 8(3): 173-177
Published online Jun 28, 2020. doi: 10.13105/wjma.v8.i3.173
Published online Jun 28, 2020. doi: 10.13105/wjma.v8.i3.173
Drug | Inhibition of viral internalization into host cells | Inhibition of viral replication in the host cells | Modulation of immune response to virus infection | Effectiveness against virus |
Hydroxychloroquine | Yes | No | Yes | Probably effective in the initial stage of the disease |
Azithromycin | Yes | Yes | Yes | Probably effective in all stages of the disease |
Indomethacin | No | Yes | Yes | Probably effective in the initial and intermediate stages of the disease |
Doxycycline | Yes | Yes | Yes | Probably effective in all stages of the disease |
Sofosbuvir with ledipasvir or with velpatasvir | No | Yes | No | Probably effective in all stages of the disease |
Ivermectin | No | Yes | No | Probably effective in all stages of the disease |
Remdesivir | No | Yes | No | Probably effective in all stages of the disease |
- Citation: Scotto Di Vetta M, Morrone M, Fazio S. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations. World J Meta-Anal 2020; 8(3): 173-177
- URL: https://www.wjgnet.com/2308-3840/full/v8/i3/173.htm
- DOI: https://dx.doi.org/10.13105/wjma.v8.i3.173